Onglyza Legal Loans – Cash Advances for Plaintiffs
Bristol-Myers Squibb and AstraZeneca Pharmaceuticals are facing a wave of lawsuits in NJ state court, filed by patients who claim that they were not sufficiently warned about the increased risks of heart failure from using Onglyza. Despite its blockbuster sales in the U.S., the diabetes drug Onglyza (saxagliptin) has been associated with a slew of dangerous side effects that increase the likelihood of suffering cardiovascular problems. Concerns over the risks of Onglyza have prompted several research studies and an FDA drug safety communication issued in 2016. After reviewing two clinical trials, federal health officials updated the warnings and precautions label to inform patients about the heightened heart failure risk with Onglyza, particularly among those who have a history of kidney or cardiovascular disease.
Onglyza heart failure lawsuits
In addition to heart failure risk, some patients have experienced other health complications when taking saxagliptin to manage blood sugar levels. Emerging studies on saxagliptin indicate that the drug may also increase the risk of chronic pancreatitis and pancreatic cancer. As of mid-2017, litigation involving Onglyza side effects has been filed in multiple states across the nation, with plaintiffs suing for hospital and medical expenses, lost wages, emotional anguish, loss of enjoyment of life and wrongful death. According to allegations leveled in Onglyza lawsuits, the defendants are accused of intentionally concealing the risks of serious adverse events with the medication, such as congestive heart failure, cardiac failure and hypoxic respiratory failure.
The legal system affords remedies to victims of dangerous and defective drugs, but product liability litigation can take years to resolve, and cost plaintiff thousands of dollars they can ill afford while struggling with lost income and piles of medical bills. Here at LawStreet Capital, we understand the financial challenges that litigation and serious injury entail, which is why we are proud to offer legal loans for Onglyza lawsuit plaintiffs.
Benefits of lawsuit funding
LawStreet Capital has earned a national reputation for providing low-rate, risk-free lawsuit funding for plaintiffs who cannot wait for their case to settle or go to trial. We know that plaintiffs – especially the former bread-winners who can no longer afford to pay the mortgage or pay for a child’s education – may look to settling a case early just to make ends meet. With our legal funding solutions, you never have to settle for less than you deserve. Our legal loans are just another name for a cash advance that is based on the strength of your case. This lawsuit cash advance is available to plaintiffs on a non-recourse basis, meaning we assume all risk if the case is lost.
Check out some of the many benefits of our legal loans:
- Approval process takes just 24 hours
- No credit check or employment verification needed
- No collateral
- No hidden costs
- No payment plans
- Competitive interest rates
- Use the money ANY way you want
- You only pay us back if you win or settle your lawsuit
If you’re still wondering if pre settlement funding is right for you, keep in mind that the application is free and without obligation to proceed. Our representatives will contact your legal counsel and determine the amount of your cash advance based on your anticipated settlement recovery. When you work with LawStreet Capital, you can be assured of the best rates in the industry because we are a direct lender.
Apply for a risk free Onglyza legal loan
Legal loans offer breathing space if you are unable to cover day-to-day expenses like car payments, rent, mortgage or hospital bills while waiting for your lawsuit to resolve, letting you hold out for a fair settlement or court award. To learn more about our cash advances for plaintiffs, we invite you to contact us today or start your free application online! Call LawStreet Capital at 866-FUND-662 to start the process today.
Additional “Onglyza lawsuit” Resources:
- New Jersey Law Journal, Drugmakers Face Suits Linking Diabetes Med to Heart Failure http://www.njlawjournal.com/id=1202785215432/Drugmakers-Face-Suits-Linking-Diabetes-Med-to-Heart-Failure?mcode=0&curindex=0&curpage=ALL&slreturn=20170709123642
- New England Journal of Medicine, Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus http://www.nejm.org/doi/full/10.1056/NEJMoa1307684
- Fierce Pharma, Onglyza’s label should flag heart failure risks, FDA panel says http://www.fiercepharma.com/regulatory/onglyza-s-label-should-flag-heart-failure-risks-fda-panel-says